Edesa Biotech commenced an underwritten public offering on August 19, 2026. The offering includes common shares, pre-funded warrants, and accompanying common share warrants.
Guggenheim Securities is serving as the sole book-running manager for the transaction. The final size and terms of the offering remain subject to market conditions.
Edesa plans to use the net proceeds for general corporate purposes and working capital. The capital will also fund expenses related to research, development, and manufacturing.
The offering proceeds under a shelf registration statement declared effective by the SEC on September 9, 2025.